SARS-CoV-2 Spike Antikörper (C-Term)

Produktnummer ABIN1030641

Produktdetails anti-SARS-CoV-2 Spike Antikörper

Target: SARS-CoV-2 Spike

Bindungsspezifität: C-Term

Reaktivität: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV)

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser SARS-CoV-2 Spike Antikörper ist unkonjugiert

Applikation: ELISA, Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (IHC)

Homologie: Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (100%)

Aufreinigung: Affinity chromatography purified via peptide column

Immunogen: Anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Spike antibody was raised against a peptide corresponding to 20 amino acids near the carboxy terminus of SARS-CoV-2 (COVID-19, 2019-nCoV) Spike glycoprotein.
The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19, 2019-nCoV) Spike protein.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: 1 μg/mL; IF: 1 μg/mL. IHC: 0.2 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: The antibody is supplied in PBS containing 0.02% sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.

Haltbarkeit: 12 months

Referenzen für anti-SARS-CoV-2 Spike Antikörper (ABIN1030641)

El Jamal, Pujadas, Ramos, Bryce, Grimes, Amanat, Tsankova, Mussa, Olson, Salem, Miorin, Aydillo, Schotsaert, Albrecht, Liu, Marjanovic, Francoeur, Sebra, Sealfon, García-Sastre, Fowkes, Cordon-Cardo et al.: "Tissue-Based SARS-Cov-2 Detection in Fatal COVID-19 Infections: Sustained Direct Viral-Induced Damage is Not Necessary to Drive Disease Progression. ..." in: Human pathology, (2021) (PubMed).

Garifullina, Shen: "High-throughput fabrication of high aspect ratio Ag/Al nanopillars for optical detection of biomarkers." in: Journal of materials chemistry. B, (2021) (PubMed).

Magro, Mulvey, Berlin, Nuovo, Salvatore, Harp, Baxter-Stoltzfus, Laurence: "Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases." in: Translational research : the journal of laboratory and clinical medicine, Vol. 220, pp. 1-13, (2020) (PubMed).

Mulvey, Magro, Ma, Nuovo, Baergen: "Analysis of complement deposition and viral RNA in placentas of COVID-19 patients." in: Annals of diagnostic pathology, Vol. 46, pp. 151530, (2020) (PubMed).

Nuovo, Tili, Suster, Matys, Hupp, Magro et al.: "Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG ..." in: Annals of diagnostic pathology, Vol. 48, pp. 151600, (2020) (PubMed).

Nuovo, Magro, Mikhail: "Cytologic and molecular correlates of SARS-CoV-2 infection of the nasopharynx." in: Annals of diagnostic pathology, Vol. 48, pp. 151565, (2020) (PubMed).

Nuovo, Magro, Shaffer, Awad, Suster, Mikhail, He, Michaille, Liechty, Tili: "Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein." in: Annals of diagnostic pathology, Vol. 51, pp. 151682, (2020) (PubMed).

Ventura, Cennamo, Minopoli, Campanile, Censi, Terracciano, Portella, Velotta: "Colorimetric Test for Fast Detection of SARS-CoV-2 in Nasal and Throat Swabs." in: ACS sensors, Vol. 5, Issue 10, pp. 3043-3048, (2020) (PubMed).

Funari, Chu, Shen: "Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip." in: Biosensors & bioelectronics, Vol. 169, pp. 112578, (2020) (PubMed).

Details zu SARS-CoV-2 Spike

Target: SARS-CoV-2 Spike

Abstract: SARS-CoV-2 Spike Produkte

Synonyme: E2 antikoerper, E2 glycoprotein precursor antikoerper, Surface Glycoprotein antikoerper, S antikoerper

Substanzklasse: Viral Protein

Hintergrund: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak. The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection. The spike protein is the major target for neutralizing antibodies and vaccine development. The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19. The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein .

NCBI Accession: QHD43416